Showing results (511-520 of 610) with videos related to
Sort By:
Pageof 61
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2019
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001A T Shaw, G J Riely, Y-J Bang, et al.Journal of the Air & Waste Management Association (1995)|September 11, 2020
Methane flux from flowback operations at a shale gas siteJacob T Shaw, Grant Allen, Joseph Pitt, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancerJ-C Soria, S N Ho, M Varella-Garcia, et al.ACS Sensors|September 16, 2020
Toward Long-Term Accurate and Continuous Monitoring of Nitrate in Wastewater Using Poly(tetrafluoroethylene) (PTFE)-Solid-State Ion-Selective Electrodes (S-ISEs)Yingzheng Fan, Yuankai Huang, Will Linthicum, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2018
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung CancerAlexa B Schrock, Allison Welsh, Jon H Chung, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|May 26, 2017
Synthesis of Benzodihydrofurans by Asymmetric C-H Insertion Reactions of Donor/Donor Rhodium CarbenesKellan N Lamb, Richard A Squitieri, Srinivasa R Chintala, et al.Science Translational Medicine|January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung CancersRyohei Katayama, Alice T Shaw, Tahsin M Khan, et al.Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET InhibitorIbiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.Pageof 61